ERBB2 and breast cancer: Breast cancer, e.g. four molecular subtypes (i.e. ER+/luminal-like, basal-like, HER2-enriched, and normal-like) with distinct clinical responses to treatments have been identified through gene expression data (Perou et al. 2000, van 't Veer et al. 2002).